Distinct functions of COX-1 and COX-2

Prostaglandins and Other Lipid Mediators

Volumn 68-69, Issue , 2002, Pages 165-175

  Morita, Ikuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

COX 1; COX 2; Knockout mouse

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN H2; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ARTICLE; CARCINOGENESIS; CATALYSIS; CELL CULTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME LOCALIZATION; HOMEOSTASIS; HUMAN; INFLAMMATION; KIDNEY FUNCTION; NONHUMAN; OXYGENATION; PHENOTYPE; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; ANIMAL; CARDIOVASCULAR SYSTEM; KIDNEY; METABOLISM; NEOPLASM; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HUMANS; INFLAMMATION; ISOENZYMES; KIDNEY; MEMBRANE PROTEINS; NEOPLASMS; PHENOTYPE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; TISSUE DISTRIBUTION;

EID: 0036669379     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(02)00029-1     Document Type: Article

References (74)

1. Weissmann G. Prostaglandins as modulators rather than mediators of inflammation. J. Lipid Med. 6:1993;275-286.
2. Raisz L.G. Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism. J Nutr. 125:1995;2024S-2027S.
3. Richards J.S., Russell D.L., Robker R.L., Dajee M., Alliston T.N. Molecular mechanisms of ovulation and luteinization. Mol. Cell Endocrinol. 145:1998;47-54.
4. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 18:1999;7908-7916.
5. Kraemer S.A., Meade E.A., DeWitt D.L. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch. Biochem. Biophys. 293:1992;391-400.
6. Vane J.R., Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am. J. Med. 104:1998;2S-8S.
7. Smith C.J., Morrow J.D., Roberts L.J. II, Marnett L.J. Differentiation of monocytoid THP-1 cells with phorbol ester induces expression of prostaglandin endoperoxide synthase-1 (COX-1). Biochem. Biophys. Res. Commun. 192:1993;787-793.
8. Kitzler J., Hill E., Hardman R., Reddy N., Philpot R., Eling T.E. Analysis and quantitation of splicing variants of the TPA-inducible PGHS-1 mRNA in rat tracheal epithelial cells. Arch. Biochem. Biophys. 316:1995;856-863.
9. Murakami M., Matsumoto R., Urade Y., Austen K.F., Arm J.P. C-kit ligand mediates increased expression of cytosolic phospholipase A2, prostaglandin endoperoxide synthase-1, and hematopoietic prostaglandin D2 synthase and increased IgE-dependent prostaglandin D2 generation in immature mouse mast cells. J. Biol. Chem. 270:1995;3239-3246.
10. Ueda N., Yamashita R., Yamamoto S., Ishimura K. Induction of cyclooxygenase-1 in a human megakaryoblastic cell line (CMK) differentiated by phorbol ester. Biochim. Biophys. Acta. 1344:1997;103-110.
11. Okahara K., Sun B., Kambayashi J. Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arteriol. Thromb. Vascul. Biol. 18:1998;1922-1926.
12. Bryant C.E., Appleton I., Mitchell J.A. Vascular endothelial growth factor upregulates constitutive cyclooxygenase-1 in primary bovine and human endothelial cells. Life Sci. 62:1998;2195-2201.
13. Diaz A., Chepenik K.P., Korn J.H., Reginato A.M., Jimenez S.A. Differential regulation of cyclooxygenases-1 and -2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp. Cell Res. 241:1998;222-229.
14. Forwood M.R., Kelly W.L., Worth N.F. Localisation of prostaglandin endoperoxide H synthase (PGHS)-1 and PGHS-2 in bone following mechanical loading in vivo. Anat. Rec. 252:1998;580-586.
15. Jun S.S., Chen Z., Pace M.C., Shaul P.W. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. J. Clin. Invest. 102:1998;176-183.
16. Bogar L.J., Bartula L.L., Parkman H.P., Myers S.I. Enhanced bradykinin-stimulated prostaglandin release in the acutely inflamed guinea pig gallbladder is due to new synthesis of cyclooxygenase-1 and prostacyclin synthase. J. Surg. Res. 84:1999;71-76.
17. Onodera M., Morita I., Miyazaki K., Murota S. High molecular hyaluronic acid inhibited angiogenesis and IL-1-induced PGE2 production in synovial cells isolated from rheumatoid arthritis. Mediat. Inflam. 8:1999;S19.
18. Wang J, Morita I, Onodera M, Murota S [unpublished data].
19. Xu X.M., Tang J.L., Chen X., Wang L.H., Wu K.K. Involvement of two Sp1 elements in basal endothelial prostaglandin H synthase-1 promoter activity. J. Biol. Chem. 272:1997;6943-6950.
20. Alroy I., Soussan L., Seger R., Yarden Y. Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor. Mol. Cell Biol. 19:1999;1961-1972.
21. Krikun G., Schatz F., Mackman N., Guller S., Demopoulos R., Lockwood C.J. Regulation of tissue factor gene expression in human endometrium by transcription factors Sp1 and Sp3. Mol. Endocrinol. 14:2000;393-400.
22. Chen B.K., Chang W.C. Functional interaction between c-jun and promoter factor Sp1 in epidermal growth factor-induced gene expression of human 12(S)-lipoxygenase. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10406-10411.
23. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostagland Lipid Mediat 2000;68-9:95-114.
24. Niiro H., Otsuka T., Izuhara K., Yamaoka K., Ohshima K., Tanabe T.et al. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood. 89:1997;1621-1628.
25. Migita K., Tanaka H., Okamoto K., Yoshikawa N., Ichinose Y., Urayama S.et al. FK506 augments glucocorticoid-mediated cyclooxygenase-2 downregulation in human rheumatoid synovial fibroblasts. Lab. Invest. 80:2000;135-141.
26. Gonzalez M.V., Jimenez B., Berciano M.T., Gonzalez-Sancho J.M., Caelles C., Lafarga M.et al. Glucocorticoids antagonize AP-1 by inhibiting the activation/phosphorylation of JNK without affecting its subcellular distribution. J. Cell Biol. 150:2000;1199-1208.
27. Boerboom D., Sirois J. Molecular characterization of equine prostaglandin G/H synthase-2 and regulation of its messenger ribonucleic acid in preovulatory follicles. Endocrinology. 139:1998;1662-1670.
28. Gierse J.K., McDonald J.J., Hauser S.D., Rangwala S.H., Koboldt C.M., Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. 271:1996;15810-15814.
29. Habeeb A.G., Praveen Rao P.N., Knaus E.E. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere. J. Med. Chem. 44:2001;3039-3042.
30. Bhattacharyya D.K., Lecomte M., Dunn J., Morgans D.J., Smith W.L. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. Arch. Biochem. Biophys. 317:1995;19-24.
31. Laneuville O., Breuer D.K., Xu N., Huang Z.H., Gage D.A., Watson J.T.et al. Fatty acid substrate specificities of human prostaglandin endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid. J. Biol. Chem. 270:1995;19330-19336.
32. Smith W.L., Dewitt D.L. Prostaglandin endoperoxide H synthases-1 and -2. Adv. Immunol. 62:1996;167-215.
33. Shitashige M., Morita I., Murota S. Different substrate utilization between prostaglandin endoperoxide H synthase-1 and -2 in NIH3T3 fibroblasts. Biochim. Biophys. Acta. 1389:1998;57-66.
34. Morita I., Schindler M., Regier M.K., Otto J.C., Hori T., DeWitt D.L.et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem. 270:1995;10902-10908.
35. Schievella A.R., Regier M.K., Smith W.L., Lin L.L. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J. Biol. Chem. 270:1995;30749-30754.
36. Murakami M., Kambe T., Shimbara S., Higashino K., Hanasaki K., Arita H.et al. Different functional aspects of the group II subfamily (Types IIA and V) and type X secretory phospholipase A2s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J. Biol. Chem. 274:1999;31435-31444.
37. Chen W., Pawelek T.R., Kulmacz R.J. Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and -2. J. Biol. Chem. 274:1999;20301-20306.
38. Kulmacz R.J., Pendleton R.B., Lands W.E. Interaction between peroxidase and cyclooxygenase activities in prostaglandin endoperoxide synthase. Interpretation of reaction kinetics. J. Biol. Chem. 269:1994;5527-5536.
39. Capdevila J.H., Morrow J.D., Belosludtsev Y.Y., Beauchamp D.R., DuBois R.N., Falck J.R. The catalytic outcomes of the constitutive and the mitogen inducible isoforms of prostaglandin H2 synthase are markedly affected by glutathione and glutathione peroxidase(s). Biochemistry. 34:1995;3325-3337.
40. Kulmacz R.J., Wang L.H. Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J. Biol. Chem. 270:1995;24019-24023.
41. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C.et al. Prostaglandin synthase-1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83:1995;483-492.
42. Reese J., Zhao X., Ma W.G., Brown N., Maziasz T.J., Dey S.K. Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology. 142:2001;3198-3206.
43. Houchen C.W., Stenson W.F., Cohn S.M. Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury. Am. J. Physiol. 279:2000;G858-865.
44. Morham S.G., Langenbach R., Loftin C.D., Tiano H.F., Vouloumanos N., Jennette J.C.et al. Prostaglandin synthase-2 gene disruption causes severe renal pathology in the mouse. Cell. 83:1995;473-482.
45. Dinchuk J.E., Car B.D., Focht R.J., Johnston J.J., Jaffee B.D., Covington M.B.et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 378:1995;406-409.
46. Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E.et al. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2 deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98:2001;1294-1299.
47. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E.et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell. 87:1996;803-809.
48. Cheng H.F., Wang J.L., Zhang M.Z., Wang S.W., McKanna J.A., Harris R.C. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am. J. Physiol. 280:2001;F449-456.
49. Langenbach R., Loftin C.D., Lee C., Tiano H. Cyclooxygenase deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann. N. Y. Acad. Sci. 889:1999;52-61.
50. Zhang X., Morham S.G., Langenbach R., Young D.A. Malignant transformation and anti-neoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190:1999;451-459.
51. Loftin C.D., Trivedi D.B., Tiano H.F., Clark J.A., Lee C.A., Epstein J.A.et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc. Natl. Acad. Sci. U.S.A. 98:2001;1059-1064.
52. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Ann. Rev. Biochem. 69:2000;145-182.
53. Hartner A., Pahl A., Brune K., Goppelt-Struebe M. Upregulation of cyclooxygenase-1 and the PGE2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis. Inflam. Res. 49:2000;345-354.
54. Sato T., Morita I., Sakaguchi K., Nakahama K.I., Smith W.L., Dewitt D.L.et al. Involvement of prostaglandin endoperoxide H synthase-2 in osteoclast-like cell formation induced by interleukin-1 beta. J. Bone Min. Res. 11:1996;392-400.
55. Geng Y, Blanco F.J., Cornelisson M., Lotz M. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J. Immunol. 155:1995;796-801.
56. Hempel S.L., Monick M.M., Hunninghake G.W. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J. Clin. Invest. 93:1994;391-396.
57. Wollheim F.A. Approaches to rheumatoid arthritis in 2000. Curr. Opin. Rheumatol. 13:2001;193-201.
58. Samad T.A., Moore K.A., Sapirstein A., Billet S., Allchorne A., Poole S.et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 410:2001;471-475.
59. Jakobsson P.J., Thoren S., Morgenstern R., Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. U.S.A. 96:1999;7220-7225.
60. Matijevic-Aleksic N., Sanduja S.K., Wang L.H., Wu K.K. Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line. Biochim. Biophys. Acta. 1269:1995;167-175.
61. Catella-Lawson F., McAdam B., Morrison B.W., Kapoor S., Kujubu D., Antes L.et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Therap. 289:1999;735-741.
62. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B.et al. VIGOR study group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N. Engl. J. Med. 343:2000;1520-1528.
63. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A.et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 284:2000;1247-1255.
64. Qian H., Neplioueva V., Shetty G.A., Channon K.M., George S.E. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation. 99:1999;2979-2982.
65. Williams J.L., Borgo S., Hasan I., Castillo E., Traganos F., Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res. 61:2001;3285-3289.
66. Leach M., Frank S., Olbrich A., Pfeilschifter J., Thiemermann C. Decline in the expression of copper/zinc superoxide dismutase in the kidney of rats with endotoxic shock: effects of the superoxide anion radical scavenger, tempol, on organ injury. Br. J. Pharmacol. 125:1998;817-825.
67. Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M.et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85:1999;221-228.
68. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
69. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell. 83:1995;493-501.
70. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58:1998;362-366.
71. Bamba H., Ota S., Kato A., Kawamoto C., Matsuzaki F. Effect of prostaglandin E1 on vascular endothelial growth factor production by human macrophages and colon cancer cells. J. Exp. Clin. Cancer Res. 19:2000;219-223.
72. Majima M., Hayashi I., Muramatsu M., Katada J., Yamashina S., Katori M. Cyclooxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br. J. Pharmacol. 130:2000;641-649.
73. Komhoff M., Grone H.J., Klein T., Seyberth H.W., Nusing R.M. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am. J. Physiol. 272:1997;F460-8.
74. Nantel F., Meadows E., Denis D., Connolly B., Metters K.M., Giaid A. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett. 457:1999;475-477.